Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Jun Ma, Xu Liu et al.|New England Journal of Medicine|2019Cited by 934
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinomaYu‐Pei Chen, Jun Ma, Jianhua Yin et al.|Cell Research|2020Cited by 483
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu‐Pei Chen, Jun Ma, Xu Liu et al.|The Lancet|2021Cited by 234
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Ling‐Long Tang, Lei Chen et al.|Journal of Clinical Oncology|2022Cited by 147
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatmentJia‐Wei Lv, Jun Ma, Wei Yuan et al.|Nature Medicine|2023Cited by 104